ES
MARKETS / NASDAQ / ZNTL
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Zentalis Pharmaceuticals, Inc. ZNTL

7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-49.5%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 7-year series below
Revenue Net income
0.020.040.060.080.0-0.1201920222025
0.020.040.060.080.0-0.1201920222025

Per share
—
Diluted EPS, FY2025
EPS
0.40.81.2201920222025
0.40.81.2201920222025

The company pays no cash dividend.

Profitability
-49.5%
Return on equity, FY2025
ROE
0.250.50.751-49.5%201920222025
0.250.50.751-49.5%201920222025
Operating margin—
Net margin—
Return on assets-38.1%

Each USD of equity lost 50 cents this year.

Returned to shareholders
USD 4.6M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 4.6M
Share of profit-3.3%
Consecutive raises—

USD 4.6M in buybacks went back to shareholders in a year without profit.

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
—
Shares outstanding, FY2025
Change, 5 years+68.3%
Change, 10 years—

The share count grew 68% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 289.0M
total assets, end of FY2025
Total assetsUSD 289.0M
EquityUSD 216.2M
CashUSD 36.0M
Current ratio6.93×

Equity funds 75% of total assets.

History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.1
0.0
0.0
·
·
·
Operating income $B
−0.2
−0.2
−0.3
−0.2
−0.2
−0.1
−0.0
EBITDA $B
−0.2
−0.2
−0.3
−0.2
−0.2
−0.1
−0.0
Income tax $B
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
Net income $B
−0.1
−0.2
−0.3
−0.2
−0.2
−0.1
−0.0
EPS, diluted $
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−49.5
−42.8
−67.1
−54.6
·
·
·
Shares out B
·
·
·
·
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed